Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Nowicki

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The FEBS Journal|April 14, 2015
Oncometabolites: tailoring our genesStefan Nowicki, Eyal Gottlieb
Frontiers in Oncology|July 22, 2017
Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for GlioblastomaNatasha Lakin, Robert Rulach, Stefan Nowicki, et al.
British Journal of Neurosurgery|October 12, 2013
A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regimeMario Teo, Sean Martin, Kevin Owusu-Agyemang, et al.
Neuro-Oncology Advances|September 2, 2024
Dosimetric comparison of hippocampal-sparing technologies in patients with low-grade gliomaAoife Williamson, Peter Houston, Jennifer Paterson, et al.
Clinical and Translational Radiation Oncology|March 30, 2018
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT statusBen Fulton, Susan C Short, Allan James, et al.
International Journal of Radiation Oncology, Biology, Physics|January 11, 2024
Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM TrialSarah Derby, Mark R Jackson, Karin Williams, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The FEBS Journal|April 14, 2015
Oncometabolites: tailoring our genesStefan Nowicki, Eyal Gottlieb
Frontiers in Oncology|July 22, 2017
Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for GlioblastomaNatasha Lakin, Robert Rulach, Stefan Nowicki, et al.
British Journal of Neurosurgery|October 12, 2013
A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regimeMario Teo, Sean Martin, Kevin Owusu-Agyemang, et al.
Neuro-Oncology Advances|September 2, 2024
Dosimetric comparison of hippocampal-sparing technologies in patients with low-grade gliomaAoife Williamson, Peter Houston, Jennifer Paterson, et al.
Clinical and Translational Radiation Oncology|March 30, 2018
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT statusBen Fulton, Susan C Short, Allan James, et al.
International Journal of Radiation Oncology, Biology, Physics|January 11, 2024
Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM TrialSarah Derby, Mark R Jackson, Karin Williams, et al.
Pageof 1